OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	114
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	87
Sars-CoV2 infection in pregnant women with multiple sclerosis	84
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	70
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	60
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	59
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	50
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	49
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	43
Time to move past typical syndromes in the diagnosis of multiple sclerosis	43
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder	42
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088.	42
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab	42
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial	41
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab	41
Impact of cancer on multiple sclerosis–related healthcare and disease-modifying drug use: A multinational cohort study	41
Double-negative neuromyelitis optica spectrum disorder	39
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	36
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	36
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	35
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	35
Therapy challenges for NMOSD in a patient with HIV	34
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	33
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	32
Decentralised clinical trials in multiple sclerosis research	32

Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study	30
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary	30
Immunosenescence in multiple sclerosis: New insights and clinical implications	29
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022	29
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	29
Anti-CD20 therapy in pregnancy: Balancing risks and benefits	29